Tachycardia and Atrial Fibrillation-Related Cardiomyopathies Potential Mechanisms and Current Therapies

Atrial fibrillation (AF) is associated with an increased risk of new -onset ventricular contractile dysfunction, termed arrhythmia -induced cardiomyopathy (AIC). Although cardioembolic stroke remains the most feared and widely studied complication of AF, AIC is also a clinically important consequence of AF that portends signi ficant morbidity and mortality to patients with AF. Current treatments are aimed at restoring sinus rhythm through catheter ablation and rate and rhythm control, but these treatments do not target the underlying molecular mechanisms driving the progression from AF to AIC. Here, we describe the clinical features of the various AIC subtypes, discuss the pathophysiologic mechanisms driving the progression from AF to AIC, and review the evidence surrounding current treatment options. In this review, we aim to identify key knowledge gaps that will enable the development of more effective AIC therapies that target cellular and molecular mechanisms. (J Am Coll Cardiol HF 2024;12:605 -615) (c) 2024 by the American College of Cardiology Foundation.